The stock of Galectin Therapeutics Inc (GALT) has seen a 55.97% increase in the past week, with a 63.28% gain in the past month, and a 32.28% flourish in the past quarter. The volatility ratio for the week is 4.15%, and the volatility levels for the past 30 days are at 2.87% for GALT. The simple moving average for the last 20 days is 54.64% for GALT stock, with a simple moving average of 13.38% for the last 200 days.
Is It Worth Investing in Galectin Therapeutics Inc (NASDAQ: GALT) Right Now?
The 36-month beta value for GALT is also noteworthy at 0.55. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for GALT is 43.42M, and at present, short sellers hold a 20.50% of that float. The average trading volume of GALT on June 17, 2025 was 212.87K shares.
GALT) stock’s latest price update
The stock price of Galectin Therapeutics Inc (NASDAQ: GALT) has surged by 40.27 when compared to previous closing price of 1.49, but the company has seen a 55.97% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-12 that NORCROSS, Ga., May 12, 2025 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, presented a late-breaking oral presentation of the NAVIGATE study analysis at the EASL 2025 Congress, on May 10, 2025, in Amsterdam, Netherlands. The NAVIGATE study evaluated belapectin, a galectin-3 inhibitor, in patients with MASH cirrhosis and portal hypertension.
Analysts’ Opinion of GALT
H.C. Wainwright, on the other hand, stated in their research note that they expect to see GALT reach a price target of $12, previously predicting the price at $9. The rating they have provided for GALT stocks is “Buy” according to the report published on August 13th, 2020.
B. Riley FBR gave a rating of “Buy” to GALT, setting the target price at $11 in the report published on February 13th of the previous year.
GALT Trading at 55.13% from the 50-Day Moving Average
After a stumble in the market that brought GALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.07% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GALT starting from Shlevin Harold H., who purchase 6,500 shares at the price of $1.16 back on Dec 30 ’24. After this action, Shlevin Harold H. now owns 15,206 shares of Galectin Therapeutics Inc, valued at $7,540 using the latest closing price.
Jamil Khurram, the Chief Medical Officer of Galectin Therapeutics Inc, sale 13,654 shares at $0.88 during a trade that took place back on Dec 23 ’24, which means that Jamil Khurram is holding 26,346 shares at $12,044 based on the most recent closing price.
Stock Fundamentals for GALT
The total capital return value is set at 0.32.
Based on Galectin Therapeutics Inc (GALT), the company’s capital structure generated -17.79 points at debt to capital in total, while cash flow to debt ratio is standing at -0.35. The debt to equity ratio resting at -0.95. The interest coverage ratio of the stock is -11.95.
Currently, EBITDA for the company is -41.47 million with net debt to EBITDA at -3.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.08.
Conclusion
In summary, Galectin Therapeutics Inc (GALT) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
